We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

16 hedge funds and large institutions have $1.67M invested in Lexaria Bioscience in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

33% more funds holding

Funds holding: 12 → 16 (+4)

19% more capital invested

Capital invested by funds: $1.41M → $1.67M (+$263K)

1.5% more ownership

Funds ownership: 7.94% → 9.44% (+1.5%)

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$74.7K
2
MFG
Merit Financial Group
Georgia
+$57K
3
Two Sigma Investments
Two Sigma Investments
New York
+$46.6K
4
CC
Centiva Capital
New York
+$37.9K
5
Renaissance Technologies
Renaissance Technologies
New York
+$30.8K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$10K
2
1832 Asset Management
1832 Asset Management
Ontario, Canada
-$9K
3
VF
Virtu Financial
New York
-$2.82K
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
1
Invenomic Capital Management
Massachusetts
$1.09M – – –
Geode Capital Management
2
Geode Capital Management
Massachusetts
$148K +$2.48K +924 +2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$102K – – –
Citadel Advisors
4
Citadel Advisors
Florida
$83K +$74.7K +27,888 New
MFG
5
Merit Financial Group
Georgia
$63K +$57K +21,267 New
Two Sigma Investments
6
Two Sigma Investments
New York
$52K +$46.6K +17,401 New
CC
7
Centiva Capital
New York
$42K +$37.9K +14,159 New
Renaissance Technologies
8
Renaissance Technologies
New York
$34K +$30.8K +11,500 New
VF
9
Virtu Financial
New York
$33K -$2.82K -1,051 -9%
UBS Group
10
UBS Group
Switzerland
$12K +$4.04K +1,508 +57%
Osaic Holdings
11
Osaic Holdings
Arizona
$7K – – –
Citigroup
12
Citigroup
New York
$4K +$3.3K +1,230 New
Wells Fargo
13
Wells Fargo
California
$3K +$5 +2 +0.2%
APC
14
Aspire Private Capital
North Carolina
$1K – – –
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$1K – – –
TRCT
16
Tower Research Capital (TRC)
New York
– -$10K -3,056 Closed
1832 Asset Management
17
1832 Asset Management
Ontario, Canada
– -$9K -2,686 Closed

LEXX Hedge Fund Activity: Q2 2022 in Review

16 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q2 2022, worth a combined $1.67M — up 19% from $1.41M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new LEXX positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $74.7K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $10K sold.

  • 16 institutional investors held Lexaria Bioscience (LEXX) as of Q2 2022, up from 12 in Q1 2022.
  • Funds reported $1.67M of Lexaria Bioscience stock for Q2 2022, up 19% quarter-over-quarter.
  • 6 funds opened new Lexaria Bioscience positions in Q2 2022 and 2 closed out, a net change of +4 holders.
  • The largest Lexaria Bioscience buyer in Q2 2022 was Citadel Advisors, an estimated $74.7K added.
  • The largest Lexaria Bioscience seller in Q2 2022 was Tower Research Capital (TRC), an estimated $10K sold.

Based on aggregated 13F filings for Q2 2022.